BCM
CASC

BlueCrest Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

BlueCrest Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-29,400
Closed -$122K – 1205
2017
Q1 		$122K Buy
+29,400
New +$124K 0.01% 672

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

BlueCrest Capital Management's CASC Position: Q2 2017 in Review

BlueCrest Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2017, closing a stake of 29,400 shares — an estimated $122K sold.

BlueCrest Capital Management first reported a position in CASC in Q1 2017 and held it in 1 quarter. The position peaked at $122K in Q1 2017. 76 funds tracked by Wall St. Rank hold CASC as of Q2 2017.

  • BlueCrest Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
  • BlueCrest Capital Management sold 29,400 Cascadian Therapeutics, Inc. shares in Q2 2017, an estimated $122K.
  • BlueCrest Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q1 2017 and held it in 1 quarter.
  • BlueCrest Capital Management's Cascadian Therapeutics, Inc. position peaked at $122K in Q1 2017.
  • 76 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2017.

Based on BlueCrest Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.